癌症（英文版）2011，Vol.30Issue(5)：303-314,12.
Gastrointestinal stromal tumor and its targeted therapeutics
Gastrointestinal stromal tumor and its targeted therapeutics
Jheri Dupart 1Wei Zhang 1Jonathan C. Trent1
作者信息
- 1. Departments of Sarcoma Medical Oncology and Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
- 折叠
摘要
Abstract
Over the past 60 years, investigators of basic science, pathology, and clinical medicine have studied gastrointestinal stromal tumor (GIST) and made minor advances in patient care. Recent discoveries have led to an understanding of the biological rote of KIT and platelet-derived growth factor receptor-α in GIST and the development of the tyrosine kinase inhibitor imatinib mesylate (Gleevec, formerly STI-571), one of the most exciting examples of targeted therapy to date. The success of targeted therapy in GIST has lead to new developments in our understanding of the medical and surgical management of the disease. Intense study of GIST may lead to new paradigms in the management of cancer.关键词
Gastrointestinal stromal tumor/ KIT/ platelet-derived growth factor receptor/ imatinib mesylateKey words
Gastrointestinal stromal tumor/ KIT/ platelet-derived growth factor receptor/ imatinib mesylate引用本文复制引用
Jheri Dupart,Wei Zhang,Jonathan C. Trent..Gastrointestinal stromal tumor and its targeted therapeutics [J].癌症（英文版）,2011,30(5):303-314,12.
